A Comparative Evaluation of Mosapride Versus Metoclopramide for Enteral Feeding Intolerance in Critically Ill Patients
NCT06826443 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2025-02-17
Summary
Caring for critically ill patients in an intensive care unit (ICU) is considered a standard of care. According to the Society of Critical Care Medicine (SCCM), as a function of the complex nature of the care provided in the ICU, the ideal method to provide support to the critically ill involves the participation of a multi-professional staff.
Provision of nutrition support to the critically ill is now established as an essential part of patient care where aiming toward 100% of the predicted target may have resulted in reduced mortality and increased ventilator-free days in those who are premorbid malnourished. Despite these reported benefits, clinicians continue to deliver little more than half of the enteral nutrition (EN) they plan to provide, due to gastric motility disorders, patient intolerance and clinical interruptions. Also despite the availability of numerous clinical practice guidelines (CPGs) focused on feeding critically ill patients, observational studies have consistently demonstrated persistent and significant gaps between guideline recommendations and actual nutrition practice. Consequently, underfeeding is prevalent in the intensive care unit (ICU), with patients on average receiving only 60 % of the calories that are prescribed. Moreover, Among the barriers to adequate nutritional supply in the ICU which contributes to nutritional status deterioration, gastrointestinal disorders causing enteral feed intolerance are the most important and the most often mentioned in the literature. when gastric emptying was measured in critically ill patients, 46 % of them had evidence of delayed gastric emptying. Untreated slow gastric emptying has a plethora of clinical consequences such as vomiting, aspiration of gastric contents, pneumonia, and contributes significantly to the frequent interruptions and cessation of EN in the ICU, which results in inadequate nutritional delivery. Studies have shown an association between feeding intolerance, prolonged intensive care unit (ICU) stay, and increased risk of death.
Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patients has demonstrated the importance of the use of prokinetic drugs to improve tolerance to gastric feeding in critically ill patients and achieve earlier discharge.
Prokinetic drugs act by promoting gastric motility, increase gastric emptying, prevent the retention and reflux of gastric contents and thus provide symptomatic relief.
Most of the prokinetic drugs are efficacious with prokinetic activity but the matter of major concern is their side effect profile. The most commonly used agent is metoclopramide. Although it is the most commonly used prokinetic to treat delayed gastric emptying and facilitate early enteral feeding, adverse complications limit its use including tachyphylaxis, tardive dyskinesia on long term use and QT prolongation predisposing to cardiac arrhythmias. Several drug targets have been identified to develop new promotility agents and several new medications are under investigation to overcome the side effects caused by most of the prokinetics .
Mosapride is another available prokinetic agent that enhances gastric motility through serotonin receptor agonism; resulting in prokinetic effects. It accelerates gastric emptying, improves gastric tension and sensitivity, and has anti-emetic action.
The aim of the current study is to compare the effectiveness as well as the safety of Mosapride against metoclopramide as the first line treatment for feeding intolerance in critically ill patients.
Conditions
- Enteral Feeding Intolerance
Interventions
- DRUG
-
Mosapride Citrate Tablets
Prokinetic Drug
- DRUG
-
Metoclopramide 10mg
Prokinetic Drug
Sponsors & Collaborators
-
Ain Shams University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-02-28
- Primary Completion
- 2025-05-31
- Completion
- 2025-05-31
Countries
- Egypt
Study Locations
More Related Trials
-
The Efficacy of B6 and Metoclopramide Combination in Comparison With the Other Antiemetics
NCT06390787 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluating Neostigmine Effect on Reducing Gastric Residual Volume as Compared With Metoclopramide and Ondansetron
NCT05342818 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Metoclopramide Versus Erythromycin on on Gastric Residual Volume
NCT04682691 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance
NCT01039805 ·Status: COMPLETED ·Phase: PHASE2
-
Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide
NCT06740812 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Metoclopramide in Upper Gastrointestinal Bleed
NCT05746377 ·Status: UNKNOWN ·Phase: PHASE4
-
Intrathecal Atropine vs IV Metoclopramide for Nausea & Vomiting During CS
NCT03932578 ·Status: COMPLETED ·Phase: PHASE4
-
Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients
NCT01117376 ·Status: TERMINATED ·Phase: PHASE2
-
Metoclopramide vs Placebo for Prevention of Pneumonia in Acute Stroke
NCT04873297 ·Status: COMPLETED ·Phase: PHASE4
-
Intravenous Haloperidol Versus Ondansetron for Treatment of Established Post-operative Nausea and Vomiting
NCT02143531 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Akathisia Incidence of Slow Infusion Metoclopramide
NCT01069536 ·Status: COMPLETED ·Phase: NA
-
Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED
NCT00655642 ·Status: TERMINATED ·Phase: NA
-
Subcutaneous Route and Pharmacology of Metoclopramide
NCT02466984 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum
NCT02163434 ·Status: COMPLETED ·Phase: PHASE2
-
Usefulness of Metoclopramide to Improve Endoscopic Visualization in Upper Gastrointestinal Bleeding
NCT06297954 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Three Antiemetics in Preventing Nausea and Vomiting
NCT05533281 ·Status: COMPLETED ·Phase: PHASE4
-
An Economic Study of HSK21542 Injection for Prevention of Postoperative Nausea and Vomiting
NCT06359535 ·Status: RECRUITING ·Phase: PHASE4
-
Ondansetron Versus Metoclopramide in Treatment of Vomiting in Gastroenteritis
NCT01165866 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040
NCT00562848 ·Status: COMPLETED ·Phase: PHASE1
-
Naloxegol for Opioid-Related Gastroparesis
NCT03036891 ·Status: WITHDRAWN ·Phase: PHASE2
-
Domperidone for Chronic Nausea and Vomiting
NCT02757534 ·Status: NO_LONGER_AVAILABLE
-
Prokinetic Drugs and Enteral Nutrition
NCT00916591 ·Status: UNKNOWN
-
Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
NCT00717054 ·Status: COMPLETED ·Phase: NA
-
Washed Microbiota Transplantation for Diabetic Gastroparesis
NCT06340217 ·Status: RECRUITING ·Phase: NA
-
Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo
NCT02253524 ·Status: COMPLETED ·Phase: PHASE4